These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33682636)

  • 1. Evaluation of the post-antibiotic effect
    Berkhout J; Melchers MJ; van Mil AC; Lagarde CM; Nichols WW; Mouton JW
    J Chemother; 2021 Oct; 33(6):400-408. PubMed ID: 33682636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.
    Crandon JL; Schuck VJ; Banevicius MA; Beaudoin ME; Nichols WW; Tanudra MA; Nicolau DP
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6137-46. PubMed ID: 22985878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
    MacVane SH; Crandon JL; Nichols WW; Nicolau DP
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.
    Housman ST; Crandon JL; Nichols WW; Nicolau DP
    Antimicrob Agents Chemother; 2014; 58(3):1365-71. PubMed ID: 24342641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.
    Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Schuck VJ; Nichols WW; Mouton JW
    Antimicrob Agents Chemother; 2016 Jan; 60(1):368-75. PubMed ID: 26525790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
    Shirley M
    Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA; Smith TT; MacVane SH
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.
    Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Nichols WW; Mouton JW
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2299-304. PubMed ID: 25645843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
    Cheng K; Newell P; Chow JW; Broadhurst H; Wilson D; Yates K; Wardman A
    Drug Saf; 2020 Aug; 43(8):751-766. PubMed ID: 32602065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments.
    Kidd JM; Stein GE; Nicolau DP; Kuti JL
    J Clin Pharmacol; 2020 Feb; 60(2):172-180. PubMed ID: 31423601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
    Evans SR; Tran TTT; Hujer AM; Hill CB; Hujer KM; Mediavilla JR; Manca C; Domitrovic TN; Perez F; Farmer M; Pitzer KM; Wilson BM; Kreiswirth BN; Patel R; Jacobs MR; Chen L; Fowler VG; Chambers HF; Bonomo RA;
    Clin Infect Dis; 2019 May; 68(11):1823-1830. PubMed ID: 30239599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates.
    Idowu T; Ammeter D; Arthur G; Zhanel GG; Schweizer F
    J Antimicrob Chemother; 2019 Sep; 74(9):2640-2648. PubMed ID: 31139830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M; Sutherland C; Nicolau DP
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
    Lee M; Abbey T; Biagi M; Wenzler E
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
    Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
    J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).
    Nichols WW; Bradford PA; Stone GG
    J Antimicrob Chemother; 2022 Aug; 77(9):2341-2352. PubMed ID: 35660869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.
    Buckman SA; Krekel T; Muller AE; Mazuski JE
    Expert Opin Pharmacother; 2016 Dec; 17(17):2341-2349. PubMed ID: 27758148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
    Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
    Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
    Chahine EB; Sourial M; Ortiz R
    Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.